Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy
Nature Genetics2010Vol. 42(8), pp. 715–721
Citations Over TimeTop 1% of 2010 papers
Jordi Barretina, Barry S. Taylor, Shantanu Banerji, Alexis Ramos, Mariana Lagos‐Quintana, Penelope DeCarolis, Kinjal Shah, Nicholas D. Socci, Barbara A. Weir, Alan L. Ho, Derek Y. Chiang, Boris Reva, Craig H. Mermel, Gad Getz, Yevgenyi Antipin, Rameen Beroukhim, John E. Major, Charlie Hatton, Richard Nicoletti, Megan Hanna, Ted Sharpe, Tim Fennell, Kristian Cibulskis, Robert C. Onofrio, Tsuyoshi Saito, Neerav Shukla, Christopher Lau, Sven Nelander, Serena J. Silver, Carrie Sougnez, Agnès Viale, Wendy Winckler, Robert G. Maki, Levi A. Garraway, Alex Lash, Heidi Greulich, David E. Root, William R. Sellers, Gary K. Schwartz, Cristina R. Antonescu, Eric S. Lander, Harold Varmus, Marc Ladanyi, Chris Sander, Matthew Meyerson, Samuel Singer
Related Papers
- → Novel Models of Myxoid Liposarcoma Xenografts Mimicking the Biological and Pharmacologic Features of Human Tumors(2010)28 cited
- → Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin(2019)14 cited
- Trabectedin for Advanced Soft Tissue Sarcoma: Ten Year Real-Life Perspective.(2018)
- → Abstract 1183: PPARgamma agonist promotes adipocytic differentiation and potentiates the activity of trabectedin in myxoid liposarcoma(2016)
- → Faculty Opinions recommendation of Trabectedin and RAdiotherapy in Soft Tissue Sarcoma (TRASTS): Results of a Phase I Study in Myxoid Liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma Groups.(2020)